Ranibizumab in the Treatment of Diabetic Macular Edema: A Review of the Current Status, Unmet Needs, and Emerging Challenges

Diabetic retinopathy (more specifically diabetic macular edema, DME) is the most common cause of loss of vision in the working population in developed countries. Anti-vascular endothelial growth factor (anti-VEGF) agents considerably changed the treatment algorithms and improved prognosis of center-...

Descripción completa

Detalles Bibliográficos
Autores principales: Dervenis, Nikolaos, Mikropoulou, Athanasia Maria, Tranos, Paris, Dervenis, Panagiotis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2017
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5487872/
https://www.ncbi.nlm.nih.gov/pubmed/28484955
http://dx.doi.org/10.1007/s12325-017-0548-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5487872/
https://www.ncbi.nlm.nih.gov/pubmed/28484955
http://dx.doi.org/10.1007/s12325-017-0548-1

Ejemplares similares